Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Although experiments on animals and cells
2024-10-29

Although experiments on animals and cells indicate that antioxidant and free radical scavenging agents have protective effects against brain damage, the results of preclinical trials are not as encouraging. Edaravone is a type of free radical scavenging drug that was first used as a neuroprotective
-
The most potent compounds within the current series of
2024-10-29

The most potent compounds within the current series of compounds were therefore , , , , and , with Trelagliptin australia possessing the best selectivity towards the lyase reaction in comparison to the hydroxylase reaction, indeed, this compound was found to possess an IC value of 1210nM against
-
Song et al reported series of triazolylsalicylamide derivati
2024-10-29

Song et al. reported series of 1,2,3-triazolylsalicylamide derivatives and screened over kinase panel and found compound 31 as most potent which inhibited Aurora-A, specifically with IC50 of 0.37 μM. Compound 31 was about 10-fold more active for Aurora-A than for Aurora-B (IC50 = 3.58 μM reported se
-
and LO are members of
2024-10-29

5- and 12/15-LO are members of the lipoxygenase family that convert arachidonic myosin into lipid mediators such as leukotriene B4 (LTB) and 12()-hydroxyeicosatetraenoic acid (HETE) and 15()-HETE, respectively. Evidence from several in vitro and in vivo studies has shown that activation of the 5- a
-
br Mechanisms of GPCR internalization Like for other
2024-10-29

Mechanisms of GPCR internalization Like for other types of receptors, prolonged agonist stimulation often leads to GPCR internalization, which can occur via different pathways ∗[2], [20], [21], [22], [23]. Of these pathways, clathrin-mediated AZD1152-HQPA (CME) is the best characterized and argu
-
Introduction Preeclampsia a serious hypertensive disorder th
2024-10-29

Introduction Preeclampsia, a serious hypertensive disorder that can occur during pregnancy, is a pregnancy-related disease characterized by the onset of AZ 960 and proteinuria after the 20 t h week of gestation, and it occurs in about 5% of all pregnancies [1]. If left untreated, preeclampsia can s
-
MiR has already been implicated in the protective effects of
2024-10-29

MiR-21 has already been implicated in the protective effects of Res on lung fibrosis, but the molecular mechanisms are underexplored. Our results showed a clear increase of activation protein 1 (AP-1) activity after TGF-β treatment, which was suppressed by Res in a dose-dependent manner, suggesting
-
LY 255283 Introduction It has long been recognized
2024-10-29

Introduction It has long been recognized that angiogenesis is critical to the growth, progression, and metastasis of many solid tumor types [1], and thus, drugs targeting the angiogenic pathway have been a topic of clinical investigation in the oncology community for many years. Angiogenesis is reg
-
First the complete canonical brain original RAS Angiotensino
2024-10-29

First, the complete canonical brain original RAS (Angiotensinogen, Renin, Angiotensin I, Angiotensin Converting Enzyme (ACE), Angiotensin II) has not been conclusively identified in any specific cell type within the brain [1]. Validated evidence for the presence of brain Angiotensinogen and ACE was
-
br Conclusions br Transparency document br Acknowledgements
2024-10-29

Conclusions Transparency document Acknowledgements This work was supported by a grant from the European Commission FP6 “Neuroprion” – Network of Excellence and Royal Veterinary College Bioveterinary science research project funding. We thank Professor Alun Williams (Cambridge University) fo
-
Interestingly metabolic dysfunction is also observed in amyo
2024-10-29

Interestingly, metabolic dysfunction is also observed in amyotrophic lateral sclerosis (ALS). Patients and mouse models of familial ALS exhibit higher levels of resting CP 154526 expenditure and lower fat-free mass, indicating a hypermetabolic phenotype. Lim et al. (2012) found that reducing AMPK a
-
br Results br Discussion Using primarily an electrophysiolog
2024-10-29

Results Discussion Using primarily an electrophysiological analysis of dysbindin-deficient hippocampal neurons in cultures and slices, we have uncovered a previously unreported role for dysbindin in enhancing CA3–CA1 AMPAR-mediated transmission. An earlier study, however, has reported a reduct
-
This development notwithstanding the chemotherapeutic treatm
2024-10-29

This development notwithstanding, the chemotherapeutic treatment for leukemia has stagnated over the last 40 years [35]. Main treatment options necessitate aggressive chemotherapy to target leukemic cells [36], [37], [38], [39]. Several limitations of current treatment options include the use of ant
-
It has been reported that
2024-10-28

It has been reported that NLRP3 product, caspase-1, is increased in the brains of AD patients and experimental AD animals. NLRP3- and caspase-1-deficient animals are resistant to experimental development of AD, and have decreased IL-1β production and significantly increased Aβ clearance (Heneka et a
-
br Conclusion br Conflict of
2024-10-28

Conclusion Conflict of Interest Author Contributions Acknowledgements This work was supported by a research grant (SR/50/AS-14/2012) from the Department of Science and Technology, New Delhi, India to CMC and CSIR Senior Research Fellowship (09/013(0339)/2010-EMR-I) to SB. Introduction
15325 records 67/1022 page Previous Next First page 上5页 6667686970 下5页 Last page